Longeveron Inc.

Analysis for Ticker: LGVN

Longeveron Inc is a biotechnology company developing cellular therapies for rare pediatric heart conditions, Alzheimer disease, and aging frailty. The math is a disaster because the company lost 22,7$ million in a single year while its cash plummeted to only 4,7$ million before a desperate financing round. They are surviving by printing millions of new shares and selling them to institutional funds for pennies while using that same cash to pay back their own salaries and cover their personal tax liabilities. To a child, this is like a lemonade stand that sells no lemonade but constantly asks parents for more money to pay the kids' allowances and their tax bills until the parents have nothing left. The mechanism of this collapse began in 07/2025 when they received approval for a heart study, but by 08/2025 they were forced into a public offering to raise 5,0$ million just to stay alive. The placement agent bank H.C. Wainwright siphoned a 7% cash fee and took 411.765 warrants. In 09/2025 the company terminated its chief executive Wa'el Hashad and handed him a severance package of 585.000$ in salary plus a 283.000$ bonus even as the business was failing. On 22/09/2025 the Nasdaq issued a formal notice that the stock price was too low to remain on the exchange.